| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Obstetrics and Gynecology (A.W.N., G.A.J.D., J.L.H.E., P.G.G.) and Angiogenesis Laboratory, Departments of Pathology and Internal Medicine (A.W.G., J.C.A.B.-T.S., V.L.J.L.T.), Research Institute for Growth and Development, Maastricht University and University Hospital, 6202 AZ Maastricht, The Netherlands
Address all correspondence and requests for reprints to: Dr. Patrick G. Groothuis, Department of Obstetrics and Gynecology, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands. E-mail: patrick.groothuis{at}path.unimaas.nl.
It is known that angiogenesis is of pivotal importance for the development of endometriosis. However, in the treatment of endometriosis patients, prevention of endometriosis lesion development only will not be sufficient as a therapy. Treatment options, aimed at interfering with established lesions, have to be developed. In this study we evaluated whether inhibition of angiogenesis by angiostatic therapy is also effective in antagonizing the sustentation of endometriosis. We evaluated the effect of the angiostatic compounds antihuman vascular endothelial growth factor, TNP-470, endostatin, and anginex on the growth of established endometriosis lesions in the nude mouse model. We show that human endometrium in the proliferative endometrium is highly angiogenic and that vascular endothelial growth factor-A is the most important angiogenesis promotory factor. The angiostatic compounds significantly decreased microvessel densities and the number of established endometriosis lesions. In the remaining lesions, the number of pericyte-protected vessels is not different in control and treated mice; however, the number of unprotected vessels was significantly reduced in the groups treated with the angiostatic agents. Our data demonstrate that inhibitors of angiogenesis effectively interfere with the maintenance and growth of endometriosis by inhibiting angiogenesis. This suggests that the use of angiostatic agents may be promising as a therapy for endometriosis.
This work was supported by an unrestricted grant from Ferring BV (Hoofddorp, The Netherlands; to A.W.N.) and by the Stichting Technische Wetenschappen (Grant MPG-5456; to A.W.G.).
Abbreviations: CD, Cycle day; EC, endothelial cell; H&E, hematoxylin and eosin; hVEGF, human VEGF;
SMA,
-smooth muscle actin; VEGF, vascular endothelial growth factor; VEGF-R, VEGF receptor; vWF, von Willebrand factor.
This article has been cited by other articles:
![]() |
H. M. Fraser, H. Wilson, A. Silvestri, K. D. Morris, and S. J. Wiegand The Role of Vascular Endothelial Growth Factor and Estradiol in the Regulation of Endometrial Angiogenesis and Cell Proliferation in the Marmoset Endocrinology, September 1, 2008; 149(9): 4413 - 4420. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. W. Laschke, C. Schwender, C. Scheuer, B. Vollmar, and M. D. Menger Epigallocatechin-3-gallate inhibits estrogen-induced activation of endometrial cells in vitro and causes regression of endometriotic lesions in vivo Hum. Reprod., July 4, 2008; (2008) den245v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Defrere, J.C. Lousse, R. Gonzalez-Ramos, S. Colette, J. Donnez, and A. Van Langendonckt Potential involvement of iron in the pathogenesis of peritoneal endometriosis Mol. Hum. Reprod., July 1, 2008; 14(7): 377 - 385. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Van Langendonckt, J. Donnez, S. Defrere, G. A.J. Dunselman, and P. G. Groothuis Antiangiogenic and vascular-disrupting agents in endometriosis: pitfalls and promises Mol. Hum. Reprod., May 1, 2008; 14(5): 259 - 268. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Fainaru, A. Adini, O. Benny, I. Adini, S. Short, L. Bazinet, K. Nakai, E. Pravda, M. D. Hornstein, R. J. D'Amato, et al. Dendritic cells support angiogenesis and promote lesion growth in a murine model of endometriosis FASEB J, February 1, 2008; 22(2): 522 - 529. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Becker, N. Rohwer, T. Funakoshi, T. Cramer, W. Bernhardt, A. Birsner, J. Folkman, and R. J. D'Amato 2-Methoxyestradiol Inhibits Hypoxia-Inducible Factor-1{alpha} and Suppresses Growth of Lesions in a Mouse Model of Endometriosis Am. J. Pathol., February 1, 2008; 172(2): 534 - 544. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Van Langendonckt, C. Punyadeera, R. Kamps, G. Dunselman, L. Klein-Hitpass, L.J. Schurgers, J. Squifflet, J. Donnez, and P. Groothuis Identification of novel antigens in blood vessels in rectovaginal endometriosis Mol. Hum. Reprod., December 1, 2007; 13(12): 875 - 886. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Sha, D. Wu, L. Zhang, X. Chen, M. Lei, H. Sun, S. Lin, and J. Lang Differentially expressed genes in human endometrial endothelial cells derived from eutopic endometrium of patients with endometriosis compared with those from patients without endometriosis Hum. Reprod., December 1, 2007; 22(12): 3159 - 3169. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Gilabert-Estelles, L.A. Ramon, F. Espana, J. Gilabert, V. Vila, E. Reganon, R. Castello, M. Chirivella, and A. Estelles Expression of angiogenic factors in endometriosis: relationship to fibrinolytic and metalloproteinase systems Hum. Reprod., August 1, 2007; 22(8): 2120 - 2127. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. W. Laschke and M. D. Menger In vitro and in vivo approaches to study angiogenesis in the pathophysiology and therapy of endometriosis Hum. Reprod. Update, July 1, 2007; 13(4): 331 - 342. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Oktem, I. Esinler, D. Eroglu, N. Haberal, N. Bayraktar, and H. B. Zeyneloglu High-dose atorvastatin causes regression of endometriotic implants: a rat model Hum. Reprod., May 1, 2007; 22(5): 1474 - 1480. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Punyadeera, V.L. Thijssen, S. Tchaikovski, R. Kamps, B. Delvoux, G.A.J. Dunselman, A.F.P.M. de Goeij, A.W. Griffioen, and P.G. Groothuis Expression and regulation of vascular endothelial growth factor ligands and receptors during menstruation and post-menstrual repair of human endometrium Mol. Hum. Reprod., June 1, 2006; 12(6): 367 - 375. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Becker, R. D. Wright, R. Satchi-Fainaro, T. Funakoshi, J. Folkman, A. L. Kung, and R. J. D'Amato A Novel Noninvasive Model of Endometriosis for Monitoring the Efficacy of Antiangiogenic Therapy Am. J. Pathol., June 1, 2006; 168(6): 2074 - 2084. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. P. Milling Smith, S. Battersby, K. J. Sales, H. O. D. Critchley, and H. N. Jabbour Prostacyclin Receptor Up-Regulates the Expression of Angiogenic Genes in Human Endometrium via Cross Talk with Epidermal Growth Factor Receptor and the Extracellular Signaling Receptor Kinase 1/2 Pathway Endocrinology, April 1, 2006; 147(4): 1697 - 1705. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Defrere, A. Van Langendonckt, R. G. Ramos, M. Jouret, M. Mettlen, and J. Donnez Quantification of endometriotic lesions in a murine model by fluorimetric and morphometric analyses Hum. Reprod., March 1, 2006; 21(3): 810 - 817. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-J. Lin, M.-D. Lai, H.-Y. Lei, and L.-Y. C. Wing Neutrophils and Macrophages Promote Angiogenesis in the Early Stage of Endometriosis in a Mouse Model Endocrinology, March 1, 2006; 147(3): 1278 - 1286. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. N. Jabbour, R. W. Kelly, H. M. Fraser, and H. O. D. Critchley Endocrine Regulation of Menstruation Endocr. Rev., February 1, 2006; 27(1): 17 - 46. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.W. Laschke, A. Elitzsch, B. Vollmar, P. Vajkoczy, and M.D. Menger Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions Hum. Reprod., January 1, 2006; 21(1): 262 - 268. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Nasu, M. Nishida, T. Ueda, N. Takai, S. Bing, H. Narahara, and I. Miyakawa Bufalin induces apoptosis and the G0/G1 cell cycle arrest of endometriotic stromal cells: a promising agent for the treatment of endometriosis Mol. Hum. Reprod., November 1, 2005; 11(11): 817 - 823. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Kim, Y. M. Choi, S. H. Choung, J. K. Jun, J. G. Kim, and S. Y. Moon Vascular endothelial growth factor gene +405 C/G polymorphism is associated with susceptibility to advanced stage endometriosis Hum. Reprod., October 1, 2005; 20(10): 2904 - 2908. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bhanoori, K. Arvind Babu, N.G. Pavankumar Reddy, K. Lakshmi Rao, K. Zondervan, M. Deenadayal, S. Kennedy, and S. Shivaji The vascular endothelial growth factor (VEGF) +405G>C 5'-untranslated region polymorphism and increased risk of endometriosis in South Indian women: a case control study Hum. Reprod., July 1, 2005; 20(7): 1844 - 1849. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Berkley, N. Dmitrieva, K. S. Curtis, and R. E. Papka Innervation of ectopic endometrium in a rat model of endometriosis PNAS, July 27, 2004; 101(30): 11094 - 11098. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |